Farmaco biologico originator o biosimilare? Una scelta complessa...per tutti

Local health authorities, physicians, drug industries and pharmacists have the duty to match financial constraints with the high level of patient’s health and safety protection. Choices implied in the adoption of an originator biologic drug, or its biosimilar, exemplifies some of the critical points that stakeholders have to cope with and manage. This paper aims at analyzing the main issues involved within the option between biologic originator and biosimilar drugs that could have a deep impact on local health authorities and physicians activities.